Profile data is unavailable for this security.
About the company
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
- Revenue in USD (TTM)0.00
- Net income in USD-88.12m
- Incorporated2011
- Employees11.00
- LocationRenovaro IncCentury City Medical Plaza2080 Century City East, Suite 906LOS ANGELES 90067United StatesUSA
- Phone+1 (212) 763-0184
- Fax+1 (845) 818-3588
- Websitehttps://renovarobio.com/
Mergers & acquisitions
Acquired company | RENB:NAQ since announced | Transaction value |
---|---|---|
Gedi Cube Bv | -87.72% | -- |